Please login to the form below
Norgine increases ProStrakan stake
Norgine has increased its stake in Scotland-based biotech ProStrakan sparking speculation that it could be to set to make a counter bid to KHK
Dutch company Norgine has raised its stake in ProStrakan to 14 per cent, which could cause Kyowa Hakko Kirin's (KHK) £292m takeover plans to falter.
At the time of writing, shares in ProStrakan stood at 132.38p, above the 130p-a-share bid agreed with the Japanese firm earlier in the week, boosted by the prospect that Norgine could be about to make a higher bid.
In mid-November, ProStrakan refused an offer from Norgine, which purchased a 13.75 per cent stake, because it was said to have undervalued the company. The Dutch company said at the time that it had "no current intention" to mount a full-scale takeover bid.
ProStrakan has a number of products in key global markets including Sancuso (granisetron transdermal), a novel skin patch for the prevention of chemotherapy-induced nausea and vomiting, and cancer pain treatment Abstral (fentanyl).
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- EU “still interested” in Valneva COVID vaccine despite UK snub
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- US demand for COVID-19 antibody treatments rising fast
- David Hunt launches independent agency The Considered
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- Live Webinar: Making Actionable Health Information More Accessible Through Point-of-Care Testing
- Robust Review: COVID19 Assessment
- Market Access Transformation (MAT) Secures First Institutional Funding Led by Silversmith Capital Partners
- IBD Registry wins Communiqué award for COVID-19 tool
- Havas Life Medicom named Agency Digital Team and leads agency wins at PM Digital Awards
- New data for Tecentriq in early-stage lung cancer
- David Hunt launches independent agency The Considered
- Live Webinar: Making Actionable Health Information More Accessible Through Point-of-Care Testing
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- WHO to test three more potential COVID-19 treatments
- UK announces COVID boosters for a “bumpy winter” ahead
- Assessing the value of interim analyses in clinical trials
PMHub
OPEN Health
OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
